Jay Worley1,2, Mary L Delaney1,3, Christopher K Cummins1, Andrea DuBois1,3, Michael Klompas4,5, Lynn Bry1,3. 1. Massachusetts Host-Microbiome Center, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, USA. 3. Clinical Microbiology Laboratory, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. 5. Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Clostridioides difficile infections (CDIs) are among the most prevalent hospital-associated infections (HAIs), particularly for intensive care unit (ICU) patients. The risks for developing active CDI from asymptomatic carriage of C. difficile are not well understood. METHODS: We identified asymptomatic C. difficile carriage among 1897 ICU patients using rectal swabs from an existing ICU vancomycin-resistant enterococci (VRE) surveillance program. C. difficile isolates from VRE swabs, and from C. difficile-positive stool samples, were genome sequenced. Spatial-temporal data from hospital records assessed genomically identified clusters for potential transmission events. RESULTS: Genomic analyses identified a diverse set of strains in infected patients and asymptomatic carriers. A total of 7.4% of ICU patients asymptomatically carried C. difficile; 69% of isolates carried an intact toxin locus. In contrast, 96% of C. difficile stool isolates were toxin encoding. CDI rates in asymptomatic carriers of toxin-encoding strains were 5.3% versus 0.57% in noncarriers. The relative risk for CDI with asymptomatic carriage of a toxin-encoding strain was 9.32 (95% confidence interval, 3.25-26.7). Genomic identification of clonal clusters supported analyses for asymptomatic transmission events, with spatial-temporal overlaps identified in 13 of 28 cases. CONCLUSIONS: Our studies provide the first genomically confirmed assessments of CDI relative risk from asymptomatic carriage of toxin-encoding strains and highlight the complex dynamics of asymptomatic transmission in ICUs. Asymptomatic carriers are an active reservoir of C. difficile in the nosocomial environment. C. difficile screening can be implemented within existing HAI surveillance programs and has the potential to support infection-control efforts against this pathogen.
BACKGROUND: Clostridioides difficile infections (CDIs) are among the most prevalent hospital-associated infections (HAIs), particularly for intensive care unit (ICU) patients. The risks for developing active CDI from asymptomatic carriage of C. difficile are not well understood. METHODS: We identified asymptomatic C. difficile carriage among 1897 ICU patients using rectal swabs from an existing ICU vancomycin-resistant enterococci (VRE) surveillance program. C. difficile isolates from VRE swabs, and from C. difficile-positive stool samples, were genome sequenced. Spatial-temporal data from hospital records assessed genomically identified clusters for potential transmission events. RESULTS: Genomic analyses identified a diverse set of strains in infected patients and asymptomatic carriers. A total of 7.4% of ICU patients asymptomatically carried C. difficile; 69% of isolates carried an intact toxin locus. In contrast, 96% of C. difficile stool isolates were toxin encoding. CDI rates in asymptomatic carriers of toxin-encoding strains were 5.3% versus 0.57% in noncarriers. The relative risk for CDI with asymptomatic carriage of a toxin-encoding strain was 9.32 (95% confidence interval, 3.25-26.7). Genomic identification of clonal clusters supported analyses for asymptomatic transmission events, with spatial-temporal overlaps identified in 13 of 28 cases. CONCLUSIONS: Our studies provide the first genomically confirmed assessments of CDI relative risk from asymptomatic carriage of toxin-encoding strains and highlight the complex dynamics of asymptomatic transmission in ICUs. Asymptomatic carriers are an active reservoir of C. difficile in the nosocomial environment. C. difficile screening can be implemented within existing HAI surveillance programs and has the potential to support infection-control efforts against this pathogen.
Authors: M Mac Aogáin; G Moloney; S Kilkenny; M Kelleher; M Kelleghan; B Boyle; T R Rogers Journal: J Hosp Infect Date: 2015-02-26 Impact factor: 3.926
Authors: Suresh Ponnada; Dubert M Guerrero; Lucy A Jury; Michelle M Nerandzic; Jennifer L Cadnum; M Jahangir Alam; Curtis J Donskey Journal: Infect Control Hosp Epidemiol Date: 2017-07-11 Impact factor: 3.254
Authors: E Meltzer; G Smollan; A Huppert; R Fluss; I Tal; M Gilboa; T Zilberman-Daniels; N Keller; G Rahav; G Regev-Yochay Journal: Clin Microbiol Infect Date: 2019-02-14 Impact factor: 8.067
Authors: Ling Yuan Kong; David W Eyre; Jacques Corbeil; Frederic Raymond; A Sarah Walker; Mark H Wilcox; Derrick W Crook; Sophie Michaud; Baldwin Toye; Eric Frost; Nandini Dendukuri; Ian Schiller; Anne-Marie Bourgault; Andrew Dascal; Matthew Oughton; Yves Longtin; Louise Poirier; Paul Brassard; Nathalie Turgeon; Rodica Gilca; Vivian G Loo Journal: Clin Infect Dis Date: 2019-01-07 Impact factor: 9.079
Authors: Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: Brintha P Girinathan; Nicholas DiBenedetto; Jay N Worley; Johann Peltier; Mario L Arrieta-Ortiz; Selva Rupa Christinal Immanuel; Richard Lavin; Mary L Delaney; Christopher K Cummins; Maria Hoffman; Yan Luo; Narjol Gonzalez-Escalona; Marc Allard; Andrew B Onderdonk; Georg K Gerber; Abraham L Sonenshein; Nitin S Baliga; Bruno Dupuy; Lynn Bry Journal: Cell Host Microbe Date: 2021-10-11 Impact factor: 21.023
Authors: Jennifer J Dawkins; Jessica R Allegretti; Travis E Gibson; Emma McClure; Mary Delaney; Lynn Bry; Georg K Gerber Journal: Microbiome Date: 2022-06-09 Impact factor: 16.837